Here are relevant reports on : parkinsons-disease-market
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022
The protein assays market is projected to reach USD 2.41 Billion by 2022, at a CAGR of 11.1%. Some of the prominent players in the market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
- Published: May 2017
- Price: $ 4950
- TOC Available:
-
Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028
The global molecular quality controls market, valued at US$0.2 billion in 2022, stood at US$0.2 billion in 2023 and is projected to advance at a resilient CAGR of 6.6% from 2023 to 2028, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The growth of this market is primarily driven by the increasing number of accredited clinical laboratories, growing adoption of third-party quality controls, and increasing government funding for genomic projects.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecasts to 2023
The global gene panel market is expected to reach USD 2.95 Billion by 2023, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Latin America In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Disease) - Forecast to 2031
The Latin America in vitro diagnostics (IVD) market, valued at USD 5.48 billion in 2025, stood at USD 5.87 billion in 2026 and is projected to advance at a resilient CAGR of 6.7% from 2026 to 2031, culminating in a forecasted valuation of USD 8.13 billion by the end of the period. The increasing demand for diagnostic services, along with the growing need for routine and specialized testing, is driving the market. Investments in lab infrastructure, combined with the adoption of automated and standardized diagnostic procedures, contribute to increasing test volumes in both the public and private healthcare sectors.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market, valued at US$7.6 billion in 2022, stood at US$9.7 billion in 2023 and is projected to advance at a resilient CAGR of 15.2% from 2025 to 2028, culminating in a forecasted valuation of US$19.8 billion by the end of the period. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Injectable Pharma Packaging Market by Type (Prefilled Syringes, Vials, Ampoules, Cartridges), Packaging Type (Primary, Secondary), Application (Chronic Disease Management, Vaccines, Biologics, Insulin, Oncology), and Region-Global Forecast to 2030
Injectable Pharma Packaging Market is projected to reach USD 98.8 billion by 2030 from USD 44.8 billion in 2025, at a CAGR of 17.5% during the forecast period. The key players in the injectable pharma packaging market include Schott AG (Germany), Gerresheimer AG (Germany), West Pharmaceutical Services (US), Stevanato Group (Italy), BD (Becton, Dickinson and Company) (US), SGD Pharma (France), Nipro Corporation (Japan), AptarGroup (US), Catalent, Inc. (US), and Datwyler Group (Switzerland).
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Respiratory Antivirals Market by Disease Type (URTI, Influenza, Bronchiolitis, Pneumonia, Measles, & Others), Drug Class (Nucleoside Analogues, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors) - Global Forecast to 2019
Over the years, there has been a significant increase in the number of viral respiratory infections in humans. As a result of this, the costs to the community have increased considerably owing to the growing number of physician visits and hospitalizations. Among approximately 200 viral respiratory pathogens, the most important viral pathogens include influenza and respiratory syncytial viruses (RSVs). Antiviral drugs play an important role in the prevention and treatment of these disorders.
- Published: October 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
